Detail akcie Uniqure online

Business Summary: Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Uniqure NV revenues decreased 41% to $16.1M. Net loss decreased 17% to $199M. Revenues reflect Collaboration revenues decrease of 98% to $164K, Contract manufacturing revenues decrease from $6.1M to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$4.92 to -$3.46.